Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-06-15

Reporting Person: Tester Jason E. (Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-15	Stock Option (right to buy)	$35.26	A	10000	Acquired	2031-06-15	Common Stock (10000)	Direct
2021-06-15	Stock Option (right to buy)	$35.26	A	10000	Acquired	2031-06-15	Common Stock (10000)	Direct

Footnotes

F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F2: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.